Combination cancer immunotherapies tailored to the tumour microenvironment

By M. Smyth, S. Ngiow, Antoni Ribas, M. Teng. Nature Reviews Clinical Oncology, 2016

846 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/675cd7706eb73406eda7b2676d64bc5262dbfb9a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. K. Flaherty
2. D. Barbie
3. Russell W. Jenkins

In Oncology

1. K. Flaherty
2. D. Barbie
3. Russell W. Jenkins

Citations in the corpus

• Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022, background): “Correspondingly, strengthening these positive elements might boost the cancer-immune cycle, drive the transformation from cold to hot tumors, and improve the response to α-PD-1/PD-L1 therapies [21].”
• Mechanisms of resistance to immune checkpoint inhibitors (2018, background): “Combination therapies to overcome innate resistance by targeting putative mechanisms of immune evasion within the TME are in various stages of development (Spranger and Gajewski, 2013; Smyth et al, 2016).”